- Stage I-IIE primary non-Hodgkin's lymphoma of the testis: results of a prospective trial by the GOELAMS Study GroupClaude Linassier
Department of Medical Oncology, CHRU Bretonneau Tours, France
Clin Lymphoma 3:167-72. 2002..The improvement in prognosis seemed to be due in part to irradiation, including the pelvic and lomboaortic lymphatic areas, and in part to CNS prophylaxis...
- Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case reportClaude Linassier
Centre Hospitalier Universitaire Bretonneau, Centre Henry S Kaplan, Department for Oncology, 2 boulevard Tonnelle, 37044 Tours cedex 9, France
Anticancer Res 32:697-700. 2012..This suggests that TKIs targeting VEGFR should be considered as individual drugs and not as a single class...
- Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancerStephane Oudard
Department of Medical Oncology, Georges Pompidou European Hospital, 20 rue Leblanc, 75908, Paris Cedex 15, France
J Clin Oncol 23:3343-51. 2005..We conducted a randomized phase II study to evaluate prostate-specific antigen (PSA) response (primary end point) and safety of two docetaxel-estramustine-prednisone (DEP) regimens and mitoxantrone-prednisone (MP)...
- Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 studyThierry Lesimple
Department of Medical Oncology, Centre Eugene Marquis, Rennes, France
J Neurooncol 93:253-60. 2009..However, while response and stabilization concerned one-third of the patients, the study did not show increased benefits in terms of survival in patients with unresectable GBM...